Trials / Completed
CompletedNCT03240237
CCM in Heart Failure With Preserved Ejection Fraction
Cardiac Contractility Modulation Therapy in Subjects With Heart Failure With Preserved Ejection Fraction
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Impulse Dynamics · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This pilot study will evaluate the efficacy and safety of CCM therapy in heart failure patients with baseline EF≥50% (HFpEF) who have New York Heart Association (NYHA) Class II or III symptoms despite appropriate medication. The terminology of the HF classification HFpEF is based on the 2016 European Society of Cardiology (ESC) Heart Failure Guidelines.
Detailed description
This is a pilot clinical study of CCM in addition to optimal medical therapy (OMT) over a 24 week period.The primary endpoint shall be mean change from baseline to 24 weeks in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score (reflecting integrated information on physical limitations, symptoms, self-efficacy, social interference and quality of life). This pilot study will collect efficacy and safety data in heart failure patients having NYHA class II and III symptoms despite appropriate medication with baseline ejection fraction equal or greater than 50% (HFpEF populations).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Optimizer SMART | Cardiac Contractility Modulation |
Timeline
- Start date
- 2018-05-01
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
- First posted
- 2017-08-07
- Last updated
- 2024-04-23
Locations
17 sites across 8 countries: Australia, Czechia, Germany, Italy, Poland, Portugal, Spain, Sweden
Source: ClinicalTrials.gov record NCT03240237. Inclusion in this directory is not an endorsement.